Format

Send to

Choose Destination
Haematologica. 2016 Apr;101(4):e133-4. doi: 10.3324/haematol.2015.136499. Epub 2015 Dec 17.

NUP214-ABL1 fusion defines a rare subtype of B-cell precursor acute lymphoblastic leukemia that could benefit from tyrosine kinase inhibitors.

Author information

1
CHU Lille, Biology and Pathology Center, Laboratory of Hematology, Lille, France INSERM UMR-S 1172, Cancer Research Institute, Lille, France nicolas.duployez@chru-lille.fr.
2
CHU Lille, Biology and Pathology Center, Laboratory of Hematology, Lille, France.
3
CHU Lille, Jeanne de Flandre Hospital, Pediatric Hematology Department, Lille, France.
4
CHU Lille, Biology and Pathology Center, Laboratory of Hematology, Lille, France INSERM UMR-S 1172, Cancer Research Institute, Lille, France.
5
Assistance Publique-Hôpitaux de Paris, Saint Louis Hospital, Laboratory of Hematology, Paris, France.

KEYWORDS:

B-cell precursor acute lymphoblastic leukemia; BCR-ABL1-like; adolescents; tyrosine kinase inhibitors

PMID:
26681761
PMCID:
PMC5004396
DOI:
10.3324/haematol.2015.136499
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center